← Leaderboards
Qien Wang
Ohio State University
$5,951,027
Attributed
$6,995,826
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,995,826 · 4
By mechanism
R01$6,995,826 · 4
Top collaborators
- Dehua Pei5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Christoph Plass$6,274,380
- Dehua Pei$17,575,721
- Hua Zhu$6,731,822
- Mark R Parthun$8,798,119
- Heather Chandler$2,907,094
Others in their field
Top investigators on “Cancer Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$394,493,843
- Gregory H Reaman · National Childhood Cancer Foundation$172,801,935
- Richard A Gibbs · Baylor College Of Medicine$159,160,442
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Mary M Horowitz · Medical College Of Wisconsin$153,900,671
- William George Nelson · Johns Hopkins University$111,434,918
Research focus
Cancer CellMalignant NeoplasmsMalignant Neoplasm Of OvaryEpithelial Ovarian CancerRecurrenceRelapsePreventCellsIn VivoPlatinumCisplatinResistancePharmaceutical PreparationsTumorMediatingIn VitroTumor ProgressionFamilyBindingPathway InteractionsMortalityExpectationDna-Directed Dna PolymeraseOvarian
Grant awards (19)
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer$271,658
R01 · FY2025 · CA · contact PI
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer$297,273
R01 · FY2024 · CA · contact PI
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction$412,864
R01 · FY2023 · CA
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer$339,618
R01 · FY2023 · CA · contact PI
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction$412,864
R01 · FY2022 · CA
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer$340,189
R01 · FY2022 · CA · contact PI
Averting recurrent and resistant ovarian tumors$490,751
R01 · FY2021 · CA · contact PI
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction$421,290
R01 · FY2021 · CA
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer$347,682
R01 · FY2021 · CA · contact PI
Averting recurrent and resistant ovarian tumors$496,748
R01 · FY2020 · CA · contact PI
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction$421,290
R01 · FY2020 · CA
Averting recurrent and resistant ovarian tumors$426,881
R01 · FY2019 · CA · contact PI
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction$421,290
R01 · FY2019 · CA
Averting recurrent and resistant ovarian tumors$451,109
R01 · FY2018 · CA · contact PI
Averting recurrent and resistant ovarian tumors$454,502
R01 · FY2017 · CA · contact PI
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance$245,556
R01 · FY2014 · CA · contact PI
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance$237,961
R01 · FY2013 · CA · contact PI
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance$253,150
R01 · FY2012 · CA · contact PI
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance$253,150
R01 · FY2011 · CA · contact PI